GLP-1 weight loss may reduce first-impression penalties in relationships and hiring

By Hugo Francisco de SouzaReviewed by Susha Cheriyedath, M.Sc.Jul 13 2026

Women who lost weight after starting GLP-1 medications were more likely to form new partnerships or enter employment, revealing how body weight may influence opportunities at the moment first impressions are formed.

Working paper: GLP-1–Induced Weight Loss and the Female Obesity Penalty. Image Credit: Love Employee / Shutterstock

In a recent non-peer-reviewed working paper released by the National Bureau of Economic Research (NBER), economist Rebecca Diamond investigated the association between glucagon-like peptide-1 (GLP-1)-induced weight loss and women's socioeconomic experiences, particularly in the context of the recent, rapid adoption of GLP-1 receptor agonists (GLP-1 RAs) in the United States.

The analysis used data from a nationwide panel and found that GLP-1 initiation and associated weight reduction were followed by higher marriage or cohabitation rates among single women and employment entry among women who were not employed at baseline. Notably, these shifts occurred primarily through the formation of new partnerships and entry into employment rather than improvements within existing relationships or jobs, suggesting that part of the economic and societal penalties that heavier women face may arise when prospective partners or employers form initial impressions.

Background

Decades of research and economic records have revealed that overweight and obese women experience distinct disadvantages in the labor and marriage markets, a phenomenon often described as the "female obesity penalty." Previous studies have established that these penalties are multidimensional but predominantly affect wages, employment opportunities, and marriage or cohabitation rates.

However, the bulk of this research has been correlational, leaving the causal mechanisms underlying weight-related challenges unclear. Specifically, the literature remains unclear on whether higher body weight affects health, mobility, or workplace productivity, or whether external biases affect women's social and economic opportunities.

Furthermore, researchers have not yet determined whether heavier women face challenges throughout their careers and relationships, or whether the impacts are concentrated at the initial stage of opportunity creation, such as hiring and partnership formation.

Previous research on substantial weight loss has largely focused on bariatric surgery, which is highly effective but is used by a relatively small, selected population with more severe obesity. This has limited researchers' ability to examine the broader socioeconomic consequences of large, non-surgical weight loss.

The recent and rapid adoption of GLP-1 RAs has created a new setting for addressing these challenges. GLP-1 RAs have demonstrated substantial, potentially sustained weight-loss effects in overweight and obese populations, providing researchers with a window into how social and economic outcomes change after large pharmacological weight loss.

About the Working Paper

The working paper aimed to estimate how GLP-1 initiation for weight loss was associated with partnership, employment, income, job mobility, health, and well-being outcomes among American women, using data from the Understanding America Study (UAS), a nationally representative internet panel tracking approximately 15,000 U.S. adults.

The analysis population comprised women aged 25 to 61 years (n = 242) who reported initiating GLP-1 RA medications for weight loss and had sufficient treatment-timing and panel data for inclusion. Individuals who reported initiating a GLP-1 primarily for diabetes management were excluded because treatment could have been prompted by the onset or worsening of illness. Participants with diabetes were not automatically excluded.

Statistical analyses used a matched difference-in-differences design, comparing the 242 GLP-1 initiators with 850 matched women who wanted to take GLP-1 medications but had not yet started them, including later adopters observed before their own treatment initiation. The researchers exactly matched participants by baseline employment and partnership status, then reweighted the comparison group using race, pre-treatment body mass index (BMI), diabetes, self-rated health, depression, work-limiting health problems, life satisfaction, household income, and treatment cohort.

The analysis tracked outcomes including partnership formation and dissolution, employment, weekly work hours, household income, job mobility, and self-reported health and well-being. Outcomes were available through the second quarter of 2026, with longer-horizon estimates calculated for quarters 6-18 after treatment initiation.

Working Paper Findings

The analysis found that the clearest changes in participants' partnership and employment outcomes occurred in areas where new relationships or employment matches could form. The statistical analyses indicated that GLP-1 RA initiation and associated weight loss were associated with an 18.3 percentage-point increase in the probability that women who were single at baseline would marry or cohabit.

The estimated increase reached 28.6 percentage points during quarters 6 to 18 after initiation, with randomization inference (RI) p = 0.006. In contrast, already-partnered women demonstrated a 0.0 percentage-point increase in relationship dissolution, with a standard error (SE) of 1.7 percentage points, indicating no detectable excess separation or divorce in this group.

Statistical evaluations of labor-based outcomes demonstrated similar patterns. Women who were not employed at baseline experienced an overall increase in employment rate of 13.2 percentage points, expanding to 26.9 percentage points during quarters 6 to 18 after initiation (RI p = 0.053). This subgroup’s unconditional weekly work hours increased by 9.9 hours during the same period (RI p = 0.044). The employment result was close to, but did not cross, the conventional 0.05 significance threshold under randomization inference.

Conversely, women already employed at baseline did not appear to experience upward job mobility following GLP-1 RA-induced weight loss. Their employment rate declined by 2.6 percentage points overall and by 4.4 percentage points after at least 1.5 years, while weekly work hours declined by approximately 1 to 1.5 hours. They also changed employers less frequently, possibly because some women wanted to retain employer-sponsored insurance coverage for the medications.

Among women who were not employed at baseline, the longer-term point estimate suggested a 0.17-standard deviation (SD) decline in life satisfaction, but the estimate was imprecise. Neither employment subgroup showed consistent improvements in subjective health or well-being, and several health estimates moved in an unfavorable direction. The author suggested that short-term increases in work-limiting health problems might partly reflect common gastrointestinal and fatigue-related adverse effects, although these effects were not directly measured. During quarters 6 to 18, work-limiting health problems declined among women who had not been employed, suggesting that improved work capacity may have contributed to their entry into the labor force.

Conclusions

The working paper's findings imply that a significant portion of the female obesity penalty may function as a "first-impression discount." The author concludes that weight loss was not associated with improved advancement within existing jobs or detectable changes in partnership status or relationship dissolution among women who were already partnered. In these incumbent settings, richer information about an individual had already accumulated. Instead, it primarily coincided with improved outcomes when new evaluators, such as hiring managers or prospective romantic partners, formed assessments of participants.

The pattern is consistent with weight-based discrimination in the formation of new social and employment matches, but the observational analysis did not directly measure discriminatory behavior and cannot exclude other explanations, such as improved physical capacity or unmeasured factors associated with treatment timing. Treatment was also defined by initiation rather than continuous use, and only 53% of starters reported current use when surveyed.

These findings raise concerns regarding equitable access to care. Since early GLP-1 RA adopters in the sample were disproportionately financially advantaged, unequal access could influence which women are able to avoid social and economic penalties associated with body size. The author also noted that using medical treatment as a potential response to discrimination raises important ethical and distributional concerns.